• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    IsoPlexis to Report Third Quarter Financial Results on November 10, 2021

    10/26/21 7:00:00 AM ET
    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ISO alert in real time by email

    BRANFORD, Conn., Oct. 26, 2021 /PRNewswire/ -- IsoPlexis Corporation (NASDAQ:ISO), a leader in functional single-cell proteomics, today announced it will report financial results for the third quarter 2021 before market open on Wednesday, November 10, 2021. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.

    (PRNewsfoto/IsoPlexis)

    Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event.

    About IsoPlexis

    IsoPlexis is a life science technology company building solutions to accelerate the development of curative medicines and personalized therapeutics. Our award-winning single-cell proteomics systems reveal unique biological activity in small subsets of cells, allowing researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. Our integrated systems, named top innovation or design by the Scientist Magazine, Fierce, BIG Innovation, Red Dot & multiple others, are used globally to advance the field of single-cell biology into new 'omic possibilities, as our customers generate solutions to overcome the challenges of complex diseases and therapeutics. Our products have been adopted by researchers around the world, including the top 15 global pharmaceutical companies by revenue and by nearly half of comprehensive cancer centers in the U.S.

    Investor Contact

    [email protected]

    Press Contact

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/isoplexis-to-report-third-quarter-financial-results-on-november-10-2021-301408360.html

    SOURCE IsoPlexis

    Get the next $ISO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ISO

    DatePrice TargetRatingAnalyst
    2/15/2022$17.00 → $12.00Overweight
    Morgan Stanley
    1/27/2022$20.00 → $15.00Outperform
    SVB Leerink
    11/19/2021$24.00Outperform
    Evercore ISI Group
    11/11/2021$17.00 → $20.00Outperform
    SVB Leerink
    11/2/2021$17.00Outperform
    SVB Leerink
    11/2/2021Outperform
    Cowen & Co.
    11/2/2021$16.00Overweight
    Morgan Stanley
    More analyst ratings